<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7511040\results\search\testTrace\results.xml">
  <result pre="yet been proven to be safe and effective for the" exact="treatment" post="of COVID-19, the disease caused by SARS-CoV-2. However, a"/>
  <result pre="the potential arrhythmogenic risks of some pharmacological therapy used in" exact="treatment" post="of COVID-19. COVID-19 and cardiovascular diseases The majority of"/>
  <result pre="CVD are at a higher risk of adverse events.3-5 The" exact="prevalence" post="of CVD in COVID-19 was studied in a meta-analysis"/>
  <result pre="cardiogenic shock.1,5-7 A multifactorial mechanism of cardiac injury in COVID-19" exact="infection" post="is suggested by previous studies on MERS and SARS"/>
  <result pre="interaction of SARS-CoV-2 with ACE2 receptors.9 Additionally, patients with COVID-19" exact="infection" post="are known to have a hypercoagulable state that in"/>
  <result pre="CYP3A4-inhibiting drug) is used to treat human immunodeficiency virus (HIV)" exact="infection" post="and is now under investigation for use in COVID-19"/>
  <result pre="antibiotic that has been used in some of the COVID-19" exact="treatment" post="regimens for its antiviral effect. This agent is well"/>
  <result pre="compared to chloroquine. It has been used experimentally in the" exact="treatment" post="of COVID-19 in combination with azithromycin and antiviral agents.15"/>
  <result pre="cohorts of patients treated with these COVID-19 drugs, with a" exact="prevalence" post="of up to 90% in some reports.17,18 Individual cases"/>
  <result pre="current pandemic continues and these drugs are prescribed â€œoff-labelâ€� as" exact="treatment" post="or as prophylaxis, correct QTc (heart rate-corrected QT interval)"/>
  <result pre="are always recommended.27 One lead continuous monitor As part of" exact="infection" post="control mechanisms for patients with established or suspected COVID-19"/>
  <result pre="patients lies with the treating clinician. When the benefit of" exact="treatment" post="outweighs the risk of arrhythmias, it would be prudent"/>
  <result pre="serum potassium; Mg: serum magnesium; TdP: torsade de pointes). COVID-19" exact="treatment" post="in patients with inherited channelopathies In patients with known"/>
  <result pre="channelopathies In patients with known inherited LQTS or Brugada syndrome," exact="treatment" post="should be undertaken only after consultation with a heart"/>
  <result pre="to reduce pro-arrhythmic risk in this population may include aggressive" exact="treatment" post="of fever, frequent QTc interval checks, cardiac pacing, or"/>
  <result pre="frequent QT assessments (e.g. once per shift) thereby allowing early" exact="detection" post="of QT prolongation and earlier implementation of countermeasures. Management"/>
  <result pre="of QT prolongation, and the correction of reversible causes and" exact="treatment" post="of life-threatening arrhythmia, namely TdP. Before starting a new"/>
  <result pre="treatment of life-threatening arrhythmia, namely TdP. Before starting a new" exact="treatment" post="with a potential risk of QT prolongation, the patient's"/>
  <result pre="have electrolyte imbalances during an acute illness such as COVID-19" exact="infection" post="so careful electrolyte monitoring is recommended. The most fearful"/>
  <result pre="major impact on health care systems around the globe. Multiple" exact="treatment" post="strategies have been published, but results have been variable."/>
  <result pre="been variable. Some of the pharmacological agents used in COVID-19" exact="treatment" post="carry arrhythmogenic risks and can cause malignant ventricular arrhythmias"/>
  <result pre="QT interval should be assessed and monitored closely throughout the" exact="treatment" post="period. Timely management of QT prolongation and ventricular arrhythmias"/>
  <result pre="ParolaP, HoangVT, MeddebL, MailheM, et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial.Int"/>
  <result pre="QTc prolongation in chronic institutionalized patients with schizophrenia on long-term" exact="treatment" post="with typical and atypical antipsychotics.Psychopharmacology . 2011;216(1):9-16.21301815 33NachimuthuS, AssarMD,"/>
 </snippets>
</snippetsTree>
